ArticleCell2015
Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer.
Registry-linked trialOpen access · bronzeAbstract read
In one paragraph
Article in Cell, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07285993 (Improving Detection and Outcomes in Patients With Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAPI PET Imaging), which is not on this map. Cited by 1,186 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
1,186citing papers in PubMed, 2 pooled it
60.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT07285993 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation
Improving Detection and Outcomes in Patients With Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAPI PET Imaging
Who cites it
1,186 citing papers in PubMed, 2 syntheses or guidelines pooled it, 1,925 citations in OpenAlex.
- ARTEMIS: An independently validated prognostic prediction model of breast cancer incorporating epigenetic biomarkers with main effects and gene-gene interactions.Journal of advanced research · 2025Pooled it
- Head-to-Head comparison of [European journal of nuclear medicine and molecular imaging · 2025Pooled it
- Molecular evaluation of residual disease following neoadjuvant chemotherapy in triple-negative breast cancer CALGB 40603 (Alliance).The Journal of clinical investigation · 2026Trial
- Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial.Annals of surgical oncology · 2025Trial
- A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders.The Journal of clinical investigation · 2025Trial
- The spatially informed mFISHseq assay resolves biomarker discordance and predicts treatment response in breast cancer.Nature communications · 2025Trial
- Pan-Cancer Quantification of Driver Alteration Transmission Across Molecular Layers Reveals Limited Propagation to Protein Abundance.International journal of cancer · 2026Article
- Long-term outcomes of invasive lobular carcinoma compared with invasive ductal carcinoma in HR-positive/HER2-negative breast cancer: a focus on luminal subtypes.Breast cancer (Tokyo, Japan) · 2026Article
- Toward targeted therapeutics for lobular breast cancer.The Journal of clinical investigation · 2026Review
- Multidisciplinary Management Considerations in Invasive Lobular Breast Cancer: It Isn't Just Ductal.Annals of surgical oncology · 2026Review
- Actionable genetic landscape and dynamics in circulating DNA from 12,827 patients with metastatic breast cancer.Nature communications · 2026Article
- Pan-cancer analysis identifies immunoproteasome as the predominant survival-associated component of antigen processing machinery.Translational oncology · 2026Article
- Not every gene is special: Modelling scale controls the false discovery rate when analysing high-throughput sequencing data.PLoS computational biology · 2026Article
- Loss of CYLD on Chromosome 16q Impairs Homologous Recombination and Genomic Stability Through TIRR Degradation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Invasive lobular breast cancer in young patients without adjuvant systemic treatment: 15-year survival outcomes.Breast cancer research and treatment · 2026Article
- Evolving patterns of co-mutations from tumor initiation to metastatic progression.Nature genetics · 2026Article
- A pre-trained large generative model for translating single-cell transcriptomes to proteomes.Nature biomedical engineering · 2026Article
- Long-term Outcomes of Slowly Proliferating Luminal A-like Invasive Lobular Carcinoma Versus Invasive Carcinoma of No Special Type.Journal of breast cancer · 2026Article
- Multidimensional Cellular Micro-Compartments to Model Invasive Lobular Carcinoma Dormancy.Advanced healthcare materials · 2026Article
- Onconeural antigen NOVA1 dysregulates RNA alternative splicing in breast cancer.RNA (New York, N.Y.) · 2026Article
1,126 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 17 institutions in 5 countries.
Giovanni CirielloDepartment of Medical Genetics, University of Lausanne (UNIL), 1011 Lausanne, Switzerland; Computational Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Michael L GatzaLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA.
Andrew H BeckDepartment of Pathology, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA.
Matthew D WilkersonDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Suhn K RhieNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, 90033, USA.
Alessandro PastoreComputational Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Hailei ZhangThe Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.
Michael McLellanThe Genome Institute, Washington University School of Medicine, MO, 63108, USA.
Christina YauBuck Institute For Research on Aging, Novato, CA, 94945, USA.
Cyriac KandothHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Reanne BowlbyCanada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, V5Z4S6, Canada.
Hui ShenCenter for Epigenetics, Van Andel Research Institute, Grand Rapids, MI, 49503, USA.
Sikander HayatComputational Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Robert FieldhouseComputational Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Susan C LesterDepartment of Pathology, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA.
Gary M K TseDepartment of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong.
Rachel E FactorDepartment of Pathology, School of Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Laura C CollinsDepartment of Pathology, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA.
Kimberly H AllisonDepartment of Pathology, School of Medicine, Stanford University Medical Center, Stanford University, Stanford, CA, USA.
Yunn-Yi ChenDepartment of Pathology and Laboratory Medicine, University of California, San Francisco, CA, 94143, USA.
Kristin JensenDepartment of Pathology, School of Medicine, Stanford University Medical Center, Stanford University, Stanford, CA, USA; VA Palo Alto Healthcare System, Palo Alto, 94304, CA, USA.
Nicole B JohnsonDepartment of Pathology, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA.
Steffi OesterreichDepartment of Pharmacology and Chemical Biology, Women's Cancer Research Center, University of Pittsburgh Cancer Institute, Pittsburgh, PA, 15232, USA.
Gordon B MillsMD Anderson Cancer Center, The University of Texas, Houston, TX, 77230, USA.
Andrew D CherniackThe Eli and Edythe L. Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.
Gordon RobertsonCanada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, V5Z4S6, Canada.
Christopher BenzBuck Institute For Research on Aging, Novato, CA, 94945, USA.
Chris SanderComputational Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Peter W LairdCenter for Epigenetics, Van Andel Research Institute, Grand Rapids, MI, 49503, USA.
Katherine A HoadleyLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Tari A KingDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
TCGA Research Network
Charles M PerouLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA. Electronic address: cperou@med.unc.edu.
Memorial Sloan Kettering Cancer Center · USUniversity of North Carolina at Chapel Hill · USBC Cancer Agency · CABeth Israel Deaconess Medical Center · USBuck Institute for Research on Aging · USVan Andel Institute · USBroad Institute · USStanford Medicine · USRutgers, The State University of New Jersey · USThe University of Texas MD Anderson Cancer Center · USUniversity of Pittsburgh · USUniversity of Southern California · USWashington University in St. Louis · USChinese University of Hong Kong · HKUnited States Department of Veterans Affairs · USUniversity of California, San Francisco · USUniversity of Utah · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MTissue Procurement & PathologyP50CA058223 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KATHERINE A. HOADLEY · 1992 to 2026
$59.3MMedical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0MGene Expression Patterns in Human Tumors Identified Using Transcript SequencingU24CA143848 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HAYES, DAVID N, PEROU, CHARLES M · 2009 to 2016
$20.8MGenome Characterization Center (GCC)U24CA143867 · NCI · BROAD INSTITUTE, INC. · PI GABRIEL, STACEY, MEYERSON, MATTHEW L. · 2009 to 2016
$17.0MUCSC-Buck Inst. Genome Data Analysis Center for TCGA Research Network (GDAC)U24CA143858 · NCI · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI BENZ, CHRISTOPHER, HAUSSLER, DAVID H · 2009 to 2016
$8.9MCANCER SUSCEPTIBILITY VARIANT DISCOVERY IN HIGH THROUGHPUT SEQUENCING DATAR01CA180006 · NCI · WASHINGTON UNIVERSITY · PI DING, LI · 2013 to 2016
$1.1MA Pathway-based approach to investigate oncogenic mechanisms in ovarian cancerR00CA166228 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI GATZA, MICHAEL L · 2015 to 2017
$747kINFORMATICS METHODS AND MODELS FOR COMPUTATIONAL PATHOLOGYK22LM011931 · NLM · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BECK, ANDREW H · 2014 to 2016
$476kA Pathway-based Approach to Investigate Oncogenic Mechanisms in Ovarian CancerK99CA166228 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GATZA, MICHAEL L · 2013 to 2014
$200kHemizygous deletion of esential genes enables a novel therqpeutic vulnerability in cancerF30CA192725 · NCI · HARVARD MEDICAL SCHOOL · PI GIBSON, WILLIAM J · 2015 to 2017
$121kNCI NIH HHS F30 CA192725NCI NIH HHS K99 CA166228NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA058223NCI NIH HHS P50-CA58223-09A1NCI NIH HHS R00 CA166228NCI NIH HHS R01 CA180006NCI NIH HHS U24 CA143848NCI NIH HHS U24 CA143858NCI NIH HHS U24 CA143867NIGMS NIH HHS T32 GM007753NLM NIH HHS K22 LM011931
Abstract
Invasive lobular carcinoma (ILC) is the second most prevalent histologic subtype of invasive breast cancer. Here, we comprehensively profiled 817 breast tumors, including 127 ILC, 490 ductal (IDC), and 88 mixed IDC/ILC. Besides E-cadherin loss, the best known ILC genetic hallmark, we identified mutations targeting PTEN, TBX3, and FOXA1 as ILC enriched features. PTEN loss associated with increased AKT phosphorylation, which was highest in ILC among all breast cancer subtypes. Spatially clustered FOXA1 mutations correlated with increased FOXA1 expression and activity. Conversely, GATA3 mutations and high expression characterized luminal A IDC, suggesting differential modulation of ER activity in ILC and IDC. Proliferation and immune-related signatures determined three ILC transcriptional subtypes associated with survival differences. Mixed IDC/ILC cases were molecularly classified as ILC-like and IDC-like revealing no true hybrid features. This multidimensional molecular atlas sheds new light on the genetic bases of ILC and provides potential clinical options.
Indexed as
Antigens, CDBreast NeoplasmsCadherinsCarcinoma, Ductal, BreastCarcinoma, LobularFemaleHepatocyte Nuclear Factor 3-alphaHumansModels, MolecularMutationOligonucleotide Array Sequence AnalysisOncogene Protein v-aktTranscriptomeAntigens, CDCadherinsCDH1 protein, humanFOXA1 protein, humanHepatocyte Nuclear Factor 3-alphaOncogene Protein v-akt
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT07285993ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.